TidalSense
AI-powered respiratory diagnosis for faster and more accessible lung disease testing.
About
TidalSense is a UK-based healthtech startup that has developed AI-powered technology to significantly reduce the testing time for lung diseases, starting with COPD (chronic obstructive pulmonary disease). Their N-Tidal Diagnose test uses a handheld device to capture a CO₂ waveform (capnogram) which is then analyzed by AI models to detect COPD in under five minutes, a drastic improvement over traditional spirometry. The company aims to transform respiratory diagnosis, making it more accessible and efficient, particularly for underserved communities. Teams look it up for HealthTech, Artificial Intelligence, Medical Devices.
Frequently asked
What does TidalSense do?
TidalSense is a HealthTech company that offers Hardware. Teams look it up for Artificial Intelligence, Medical Devices, Diagnostics. It is based in Cambridge, England, United Kingdom and was founded in 2013. Public records show about 31 people and $9M raised. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has TidalSense raised?
TidalSense has raised a total of $9M in funding. The most recent round on record is Funding Round.
Where is TidalSense headquartered?
TidalSense is headquartered in Cambridge, England, United Kingdom.
When was TidalSense founded?
TidalSense was founded in 2013.
What industry does TidalSense operate in?
TidalSense operates in HealthTech, Artificial Intelligence, Medical Devices, Diagnostics, MedTech.
How many employees does TidalSense have?
TidalSense has approximately 31 people on record.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.
Google PageSpeed mobile performance for the company’s own site. Measured by Google, not by us.